These structural differences may affect how they interact with GLP-1 receptors in the gastrointestinal tract and central nervous system, which could contribute to differences in nausea experienced
Results Twelve studies including 123,858 patients (57,699 GLP-1 RA users) were analyzed
The good news for most members is that the side effect window is front-loaded
Human lactation data remain limited, so absolute safety cannot be guaranteed
Orforglipron is under assessment for the management of obesity and T2D and may provide a competitive alternative to oral semaglutide, with less burdensome administration, as it does not require to be taken at a fasting state [24]
During this time, participants may need to attend clinic visits, follow a treatment schedule, and keep a health journal